Showing results (1-10 of 25) with videos related to
Sort By:
Pageof 3
Oncotargets and Therapy|October 7, 2014
The emerging role of class-3 semaphorins and their neuropilin receptors in oncologyPatrick Nasarre, Robert M Gemmill, Harry A DrabkinCell Adhesion & Migration|February 9, 2010
Guidance molecules in lung cancerPatrick Nasarre, Vincent Potiron, Harry Drabkin, et al.Medecine Sciences : M/S|June 30, 2005
[Semaphorins and cancers : an up 'dating']Patrick Nasarre, Bruno Constantin, Harry A Drabkin, et al.Advances in Experimental Medicine and Biology|July 5, 2007
Semaphorin signaling in the immune systemVincent Potiron, Patrick Nasarre, Joëlle Roche, et al.Melanoma Research|March 20, 2018
TRAF3-interacting protein 3, a new oncotarget, promotes tumor growth in melanomaPatrick Nasarre, Ingrid V Bonilla, John S Metcalf, et al.Neoplasia (New York, N.Y.)|April 2, 2005
Semaphorin SEMA3F has a repulsing activity on breast cancer cells and inhibits E-cadherin-mediated cell adhesionPatrick Nasarre, Sophie Kusy, Bruno Constantin, et al.Neoplasia (New York, N.Y.)|March 28, 2003
Semaphorin SEMA3F and VEGF have opposing effects on cell attachment and spreadingPatrick Nasarre, Bruno Constantin, Lydie Rouhaud, et al.Cancers|December 17, 2016
Erratum: Roche, J. et al. Global Decrease of Histone H3K27 Acetylation in ZEB1-Induced Epithelial to Mesenchymal Transition in Lung Cancer Cells. Cancers, 2013, 5, 334-356Joëlle Roche, Patrick Nasarre, Robert Gemmill, et al.Neoplasia (New York, N.Y.)|June 22, 2005
Selective suppression of in vivo tumorigenicity by semaphorin SEMA3F in lung cancer cellsSophie Kusy, Patrick Nasarre, Daniel Chan, et al.Cancer Research|February 12, 2009
Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growthPatrick Nasarre, Markus Thomas, Karoline Kruse, et al.Pageof 3